Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6 (Beclomethasone Dipropionate 100 microg Plus Formoterol 6 microg/Actuation), 2 Puffs b.i.d., Versus Seretide 500/50 (Fluticasone 500 microg Plus Salmeterol 50 microg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease.

Next Previous
Trial Profile

A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6 (Beclomethasone Dipropionate 100 microg Plus Formoterol 6 microg/Actuation), 2 Puffs b.i.d., Versus Seretide 500/50 (Fluticasone 500 microg Plus Salmeterol 50 microg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE

Most Recent Events

  • 26 May 2012 Additional locations (Germany, Hungary, Poland, United Kingdom) added as reported by European Clinical Trials Database record.
  • 02 Apr 2012 Actual patient number is 373 according to ClinicalTrials.gov.
  • 02 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top